Clinical Trials Logo

Inflammation clinical trials

View clinical trials related to Inflammation.

Filter by:

NCT ID: NCT02151877 Completed - Clinical trials for Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

Start date: July 2014
Phase: N/A
Study type: Interventional

Around 7500 neonates born yearly in the United States have complex congenital heart disease that require surgical repair in the first few days of life. The complexity of the surgical repair requires long periods of cardiopulmonary bypass (CPB) and the use of intermittent periods of low flow or complete circulatory arrest. The immature neonatal vital organs are more prone to the complications of the cardiopulmonary bypass circulation, namely ischemia/reperfusion (I/R) injury and systemic inflammatory response. Inhaled nitric oxide (NO) is used frequently in neonates for the treatment of pulmonary hypertension, Additionally, many studies have shown that NO has an anti-inflammatory effect by reducing I/R injury and endothelial dysfunction. The purpose of this pilot study is to assess the efficacy of NO administration via the CPB circuit in attenuating the CPB induced I/R injury and systemic inflammatory reaction in neonates undergoing repair of complex congenital heart defects. Specific goals will be to demonstrate that NO use via CPB will: - Decrease markers of I/R injury and systemic inflammatory response. - Decrease platelet activation leading to reduced postoperative bleeding and transfusion requirements. - Decrease postoperative organ dysfunction, and hence decrease operative mortality and postoperative morbidity. Twelve neonates undergoing repair of complex congenital heart defects will receive NO via the CPB circuit, for the duration of surgery. They will be compared to a control group of 12 similar patients. Serum levels of different ischemic reperfusion injury and inflammatory markers will be measured at different time points after surgery and will be correlated with different end organ function tests and clinical course in the postoperative period. The results will be compared between the two groups to try to determine the clinical benefit of NO administration through CPB circuit.

NCT ID: NCT02151552 Completed - Lung Inflammation Clinical Trials

Assessing NOS Uptake With PET Imaging in Lung Inflammation

Start date: May 2014
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to learn more about the basic responses of the lungs to inflammation using positron emission tomography, or PET, imaging scans of the lungs. PET is a machine that detects radiation and generates pictures using a donut-shaped scanner similar in appearance to an x-ray "CAT" or computed tomography (CT) scan or an MRI. Inflammation is the way our bodies react to irritation or injury, and involves red, warm, and often painful swelling of the affected tissue. An enzyme called inducible nitric oxide synthase (iNOS) contributes to the development of lung inflammation.

NCT ID: NCT02151409 Completed - Healthy Clinical Trials

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to develop a complement system targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic autoimmune diseases.

NCT ID: NCT02150356 Completed - Clinical trials for Incretin Hormones Plasma Levels

Effects of Aleurone-enriched Products on Cardiovascular Risk Factors

Start date: January 2014
Phase: N/A
Study type: Interventional

Very few studies have evaluated the effect of aleurone-enriched grains on cardiovascular risk factors. Price et al.(2010) have shown that 4-week supplementation of aleurone-enriched products (27 g/day of aleurone) increased betaine concentration in plasma whereas reduced homocysteine and LDL-cholesterol levels. Interestingly, aleurone had no effect on total antioxidant status or endothelial function, whereas an improvement of C-reactive protein was observed (Price RK et al, 2012). It is not known whether consumption of more than 27g/day of aleurone-enriched products with higher ferulic acid biodisponibility and longer time of treatment could influence these parameters in individuals with metabolic syndrome. Noteworthy, no studies have investigated the effect of aleurone-enriched products on fasting and postprandial glycemic homeostasis and lipid metabolism. In addition, mechanisms by which aleurone may act in vivo are still unknown. The aim of this study is to investigate whether 8 weeks supplementation with aleurone-enriched products may influence glucose and lipid metabolism, incretin hormones levels, satiety, inflammation, oxidative stress and endothelial function in overweight/obese subjects with high cardiovascular risk.

NCT ID: NCT02145936 Completed - Dyslipidemia Clinical Trials

Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation

Start date: January 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to to determine the effect of habituation to diets with different types of dietary fat (stearic, palmitic and oleic) on selected Cardiovascular Disease (CVD) risk indicators with an emphasis on inflammation.

NCT ID: NCT02141139 Not yet recruiting - Breast Neoplasms Clinical Trials

Perioperative Inflammation and Breast Cancer Outcome

Start date: September 2014
Phase: Phase 3
Study type: Interventional

It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results. surgery is main cause of inflammation for cancer patients. Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.

NCT ID: NCT02140879 Withdrawn - Pregnancy Clinical Trials

LA Moms and Babies Study (LAMBS) for Nutrition and Growth

LAMBS
Start date: April 2014
Phase: N/A
Study type: Interventional

This research study will examine how diet during pregnancy can benefit pregnancy and pregnancy outcome, such as your baby's weight. More specifically, the investigators will study the effects of two different food oils/fats that are commonly consumed to determine if one is more effective in limiting maternal inflammation during pregnancy. You are being asked to take part in this study because it will help us update and make the best dietary recommendations for pregnant women and women of child bearing ages.

NCT ID: NCT02135939 Completed - Clinical trials for Coronary Artery Disease

Vegan vs AHA Diet on Inflammation and Glucometabolic Profile in Patients With CAD

Start date: March 11, 2014
Phase: N/A
Study type: Interventional

In this randomized study the investigators aim to determine the effects of a whole-food plant-based vegan diet on markers of inflammation and glucometabolic profile in patients with cardiovascular disease. The investigators hypothesize that a whole-food plant-based vegan diet will reduce markers of inflammation and improve glucometabolic profile compared with the American Heart Association (AHA)- recommended diet at 2 months follow-up in patients with coronary artery disease (CAD). The investigators are also evaluating endothelial function using the EndoPAT device and stool microbiome.

NCT ID: NCT02135770 Completed - Clinical trials for Severe Sepsis With Septic Shock

Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis

Start date: January 2013
Phase: Phase 3
Study type: Interventional

Sepsis is a clinical syndrome which infection trigger systemic inflammatory response. Uncontrolled inflammatory process leads to multiple organ dysfunction and cause early mortality in severe sepsis. Unfractionated heparin is an anticoagulant that widely used either for DVT prophylaxis or treatment of disseminated intravascular coagulation. Heparin also have an anti-inflammatory effect through downregulates nuclear factor kappa B and tumor necrosis factor alpha. Aim of this study is to determine effects of low dose unfractionated heparin treatment on inflammation in severe sepsis patient.

NCT ID: NCT02131012 Terminated - Inflammation Clinical Trials

Intravitreal Celecoxib for Chronic Uveitis

Celecoxib
Start date: June 2015
Phase: Phase 1
Study type: Interventional

Intraocular delivery of celecoxib will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with chronic inflammation or macular edema who are unable to tolerate corticosteroids due to their side effects.